GSE252944 AKT inhibition 11 v 9 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE252944_AKT inhibition_11_v_9_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE252944_AKT inhibition_11_v_9_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE252944_AKT inhibition_11_v_9_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE252944_AKT inhibition_11_v_9_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

family with sequence similarity 174 member C

Gene

AFAP1 antisense RNA 1

Gene

SOX21 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2997

Gene

long intergenic non-protein coding RNA 2951

Gene

RNA, U6 small nuclear 33, pseudogene

Gene

RNA, 7SL, cytoplasmic 442, pseudogene

Gene

glycine cleavage system protein H

Gene

exosome component 9

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    family with sequence similarity 174 member C


  • Gene

    AFAP1 antisense RNA 1


  • Gene

    SOX21 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2997


  • Gene

    long intergenic non-protein coding RNA 2951


  • Gene

    RNA, U6 small nuclear 33, pseudogene


  • Gene

    RNA, 7SL, cytoplasmic 442, pseudogene


  • Gene

    glycine cleavage system protein H


  • Gene

    exosome component 9

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.